# Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia

> **NCT01058642** · PHASE2 · TERMINATED · sponsor: **Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 41 (actual)

## Conditions studied

- Postherpetic Neuralgia

## Interventions

- **DRUG:** ADL5747
- **DRUG:** Placebo
- **DRUG:** Pregabalin

## Key facts

- **NCT ID:** NCT01058642
- **Lead sponsor:** Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-01
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2015-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01058642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01058642, "Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT01058642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*